Feasibility of Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension

Mayo Clinic1 site in 1 country14 target enrollmentSeptember 6, 2022

ConditionsPulmonary Arterial Hypertension

Overview

Phase: N/A
Intervention: Not specified
Conditions: Pulmonary Arterial Hypertension
Sponsor: Mayo Clinic
Enrollment: 14
Locations: 1
Primary Endpoint: Adverse Events
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to test new technology and health coaching aimed to help people with PAH become more physically active in their daily lives.

Registry

clinicaltrials.gov

Start Date

September 6, 2022

End Date

June 30, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Mayo Clinic

Responsible Party

Principal Investigator

Hilary M. DuBrock, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

•Diagnosis of PAH, confirmed by right heart catheterization (mean pulmonary artery pressure of 20 mmHg or greater, pulmonary vascular resistance of 3.0 Woods units or greater, Pulmonary capillary wedge pressure of 15 mmHg or lower).
•On PAH-specific therapy which is at stable dosing (i.e., not currently titrating therapy).
•NYHA class II-III symptoms.
•Able to complete a six-minute walk test.

Exclusion Criteria

•Patients experiencing syncope or exertional syncope.
•Patients not experiencing exertional dyspnea.
•Inability to walk.
•Patients currently in pulmonary rehab or having completed pulmonary rehab within three months (unlikely to improve).